The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Sarcopenic obesity
Abstract
Sarcopenic obesity, a chronic condition, is today a major public health problem with increasing prevalence worldwide, which is due to progressively aging populations, the increasing prevalence of obesity, and the changes in lifestyle during the last several decades. Patients usually present to healthcare facilities for obesity and related comorbidities (type 2 diabetes mellitus, non-alcoholic fatty liver disease, dyslipidemia, hypertension, and cardiovascular disease) or for non-specific symptoms related to sarcopenia per se (e.g., fatigue, weakness, and frailty). Because of the non-specificity of the symptoms, sarcopenic obesity remains largely unsuspected and undiagnosed. The pathogenesis of sarcopenic obesity is multifactorial. There is interplay between aging, sedentary lifestyle, and unhealthy dietary habits, and insulin resistance, inflammation, and oxidative stress, resulting in a quantitative and qualitative decline in muscle mass and an increase in fat mass. Myokines, including myostatin and irisin, and adipokines play a prominent role in the pathogenesis of sarcopenic obesity. It has been suggested that a number of disorders affecting metabolism, physical capacity, and quality of life may be attributed to sarcopenic obesity, although it is not as yet established whether sarcopenia and obesity act synergistically. There is to date no approved pharmacological treatment for sarcopenic obesity. The cornerstones of its management are weight loss and adequate protein intake combined with exercise, the latter in order to reduce the loss of muscle mass observed during weight loss following diet unpaired with exercise. A consensus on the definition of sarcopenic obesity is considered essential to facilitate the performance of mechanistic studies and clinical trials aimed at deepening our knowledge, thus enabling improved management of affected individuals in the near future.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SO have high fat mass, low muscle mass, low muscle strength, and low physical function.”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [3]
In the citing paper
“Sarcopenic obesity (SO) is a combination of obesity and sarcopenia that primarily develops in older people.”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [3]
In the citing paper
“Studies have found that fat tends to move to viscera, muscle and abdomen with age, and the ectopic fat cause disorders of inflammatory factors, insulin and hormones, thus resulting in SO (15).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [15]
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Flegal, K. M., Kit, B. K., Orpana, H., & Graubard, B. I. (2013) · JAMA · doi:10.1001/jama.2012.113905 · Cited by 3,998
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256 · cited 3×
“With many different recommendations, it is unsurprising that the perceived prevalence of sarcopenia varies: it is lower when the three criteria are required (FNIHSP) [11] but higher when two criteria are required [4, 9, 10], as shown in a comparative study [12].”
BackgroundStudenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545 · cited 3×
“With many different recommendations, it is unsurprising that the perceived prevalence of sarcopenia varies: it is lower when the three criteria are required (FNIHSP) [11] but higher when two criteria are required [4, 9, 10], as shown in a comparative study [12].”
BackgroundMourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Longitudinal study of muscle strength, quality, and adipose tissue infiltration
Delmonico, M. J., Harris, T. B., Visser, M., Park, S. W., Conroy, M. B., Velasquez-Mieyer, P., Boudreau, R., Manini, T. M., Nevitt, M., Newman, A. B., et al. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28047 · Cited by 1,446
Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis
Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.-Y., & Bruyère, O. (2017) · PLOS ONE · doi:10.1371/journal.pone.0169548 · Cited by 1,272
Research works printed but not linked: 2
- Polyzos SA, Kountouras J, Mantzoros CS (2017) Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol 42:92–108
- An KO, Kim J (2016) Association of sarcopenia and obesity with multimorbidity in Korean adults: a nationwide cross-sectional study. J Am Med Dir Assoc 17(960):e961–e967
Cited by
Barrera, G., Pizzimenti, S., Daga, M., Dianzani, C., Arcaro, A., Cetrangolo, G. P., Giordano, G., Cucci, M. A., Graf, M., & Gentile, F. (2018) · Antioxidants · doi:10.3390/antiox7080102 · Cited by 326
Oxidative stress: Roles in skeletal muscle atrophy
Zhang, H., Qi, G., Wang, K., Yang, J., Shen, Y., Yang, X., Chen, X., Yao, X., Gu, X., Qi, L., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115664 · Cited by 301
Bilski, J., Pierzchalski, P., Szczepanik, M., Bonior, J., & Zoladz, J. (2022) · Cells · doi:10.3390/cells11010160 · Cited by 251
“The increasing incidence of SO and its serious consequences make it a significant health burden in an ageing population due to the frequency of serious complications [22].”
BackgroundDiabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Makri, E., Goulas, A., & Polyzos, S. A. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.11.010 · Cited by 204
Metadata
- Authors
- Polyzos, S. A., & Margioris, A. N.
- Affiliations
- University of Crete (GR)
- Venue
- Hormones
- Published
- 2018-07-16
- Volume
- 17
- Issue
- 3
- Pages
- 321-331
- ISSN
- 1109-3099 (ISSN-L)
- 2520-8721
- OpenAlex
- W4234165494
- Cited by
- 212
- References
- 90
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 22 · 2023: 31 · 2022: 36 · 2021: 35 · 2020: 24 · 2019: 17 · 2018: 1
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- HORMONES (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- sarcopenic obesity, sarcopenia, obesity, muscle mass loss, fat mass, aging, sedentary lifestyle, insulin resistance, inflammation, oxidative stress, myostatin, irisin, adipokines, myokines, weight loss, protein intake, physical activity, frailty, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, dyslipidemia, hypertension
- MeSH terms
- Aging, Humans, Life Style, Obesity, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenic obesity. https://app.cochat.ai/papers/10.1007/s42000-018-0049-x
- The paper
- Polyzos, S. A., & Margioris, A. N. (2018). Sarcopenic obesity. Hormones. https://doi.org/10.1007/s42000-018-0049-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.